UY31612A1 - Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica - Google Patents

Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica

Info

Publication number
UY31612A1
UY31612A1 UY031612A UY31612A UY31612A1 UY 31612 A1 UY31612 A1 UY 31612A1 UY 031612 A UY031612 A UY 031612A UY 31612 A UY31612 A UY 31612A UY 31612 A1 UY31612 A1 UY 31612A1
Authority
UY
Uruguay
Prior art keywords
carboxamids
silanilo
preparation
group
application
Prior art date
Application number
UY031612A
Other languages
English (en)
Inventor
Malanda Andre
Yannick Evanno
Laurent Dubois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31612A1 publication Critical patent/UY31612A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Abstract

Compuestos derivados del INDOL2-CARBOXAMIDA Y DE AZAINDOL2-CARBOXAMIDA SUSTITUIDAS CON UN GRUPO SILANILO de fórmula general (I), en el estado de base o de sal de adición a un ácido, así como en el estado de hidrato o de solvato, donde los sustituyentes e índices son tales como se especifican en la memoria descriptiva y en las reivindicaciones. Procedimiento de preparación y aplicación en terapéutica para prevenir o tratar patologías en las que están implicados los receptores de tipo TRPV1.
UY031612A 2008-01-23 2009-01-23 Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica UY31612A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0800343A FR2926553B1 (fr) 2008-01-23 2008-01-23 Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY31612A1 true UY31612A1 (es) 2009-08-31

Family

ID=39671700

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031612A UY31612A1 (es) 2008-01-23 2009-01-23 Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica

Country Status (23)

Country Link
US (1) US8399491B2 (es)
EP (1) EP2235003B1 (es)
JP (1) JP5508287B2 (es)
KR (1) KR20100115358A (es)
CN (1) CN102143956B (es)
AR (1) AR070214A1 (es)
AU (1) AU2009221032B2 (es)
BR (1) BRPI0906634A2 (es)
CA (1) CA2712921C (es)
CL (1) CL2009000127A1 (es)
CO (1) CO6220974A2 (es)
EA (1) EA201070874A1 (es)
FR (1) FR2926553B1 (es)
IL (1) IL207079A0 (es)
MA (1) MA32087B1 (es)
MX (1) MX2010008101A (es)
MY (1) MY150289A (es)
NZ (1) NZ586964A (es)
PE (1) PE20091307A1 (es)
TW (1) TW200936578A (es)
UY (1) UY31612A1 (es)
WO (1) WO2009109710A1 (es)
ZA (1) ZA201005242B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
PT2981536T (pt) 2013-04-03 2017-08-09 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b
HUE040446T2 (hu) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
NZ717629A (en) 2013-10-23 2021-12-24 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
CN105820104B (zh) * 2016-03-10 2018-12-11 温州医科大学 一种具有抗炎作用的吲哚-2-酰胺类化合物及其在制备抗炎药物中的应用
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
AU2018313094A1 (en) 2017-08-07 2020-02-20 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
KR20200131816A (ko) 2018-03-14 2020-11-24 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 캡시드 조립 조절제 투약 요법
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
AU2019203034B1 (en) 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE416168T1 (de) * 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US20050197364A1 (en) * 2003-10-07 2005-09-08 Kelly Michael G. Amide compounds as ion channel ligands and uses thereof
MXPA06008201A (es) * 2004-01-23 2006-08-31 Amgen Inc Ligandos del receptor de vanilloide y su uso en tratamientos.
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
FR2903985B1 (fr) * 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) * 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
FR2910473B1 (fr) * 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
US8399491B2 (en) 2013-03-19
AR070214A1 (es) 2010-03-25
FR2926553A1 (fr) 2009-07-24
ZA201005242B (en) 2011-09-28
CA2712921C (fr) 2016-08-02
KR20100115358A (ko) 2010-10-27
FR2926553B1 (fr) 2010-02-19
CA2712921A1 (fr) 2009-09-11
CL2009000127A1 (es) 2010-02-12
AU2009221032A1 (en) 2009-09-11
CO6220974A2 (es) 2010-11-19
IL207079A0 (en) 2010-12-30
PE20091307A1 (es) 2009-09-21
WO2009109710A1 (fr) 2009-09-11
EP2235003B1 (fr) 2012-12-19
EA201070874A1 (ru) 2011-02-28
TW200936578A (en) 2009-09-01
NZ586964A (en) 2012-06-29
US20110009365A1 (en) 2011-01-13
MX2010008101A (es) 2010-08-04
MA32087B1 (fr) 2011-02-01
BRPI0906634A2 (pt) 2015-07-14
JP2011510052A (ja) 2011-03-31
JP5508287B2 (ja) 2014-05-28
EP2235003A1 (fr) 2010-10-06
CN102143956A (zh) 2011-08-03
MY150289A (en) 2013-12-31
AU2009221032B2 (en) 2013-09-26
CN102143956B (zh) 2014-04-23

Similar Documents

Publication Publication Date Title
UY31612A1 (es) Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica
UY31606A1 (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
UY31608A1 (es) Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica
UY31607A1 (es) Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica
UY36907A (es) Nuevas carboxamidas de acción microbiocida
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CR20160098A (es) Polimorfo de los inhibidores de la syk
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
CU20110052A7 (es) Compuestos orgánicos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
NI201400043A (es) 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
ECSP11011244A (es) Nuevos herbicidas.
EA201690844A1 (ru) Ингибиторы gsk-3
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140729